Kisspeptin-10 raises LH and testosterone in men in IV studies

What is kisspeptin-10?

Kisspeptin-10 is the minimal active fragment of the KISS1 gene product, a decapeptide that binds KISS1R, also called GPR54, on hypothalamic GnRH neurons. Kisspeptin neurons fire in bursts, and each burst prompts GnRH neurons to release a pulse of GnRH. That pulse drives the pituitary to release LH and FSH, and in men LH drives testicular testosterone production. Forums describe kisspeptin as the upstream master signal of the reproductive axis, and that description is accurate.

Why might repeated kisspeptin-10 dosing suppress testosterone?

KISS1R is a G-protein-coupled receptor, and continuous exposure to an agonist desensitizes receptors in this family. The same logic explains why continuous GnRH agonist treatment is used clinically to shut the reproductive axis down rather than turn it up: sustained occupancy internalizes and desensitizes the receptor, and LH output falls even though the drug is still present.

None of the studies cited below tests whether daily or every-other-day subcutaneous kisspeptin-10 lands on the stimulatory or the suppressive side of that curve. The question is open in both directions, and forum protocols do not address it.

How much does kisspeptin-10 raise LH and testosterone?

In healthy men, a 1 mcg/kg IV bolus of kisspeptin-10 raised LH from 4.1 to 12.4 IU/L within 30 minutes, and continuous infusion raised testosterone from 16.6 to 24.0 nmol/L while increasing LH pulse frequency ^[1]. A separate trial found the effect at IV doses as low as 0.3 nmol/kg in men ^[2].

The response depends on sex and hormonal state. The same compound, at doses up to 10 nmol/kg, failed to move gonadotropins in women in the follicular phase ^[2]. A result in men does not transfer to women, or across cycle phases.

Does kisspeptin-10 work in men with low testosterone?

Yes, acutely, in men with type 2 diabetes and mild hypogonadism. An IV kisspeptin-10 infusion in that group raised LH from 3.9 to 20.7 IU/L and testosterone from 8.5 to 11.4 nmol/L (P=0.002), so the hypothalamic side of the axis still responded when baseline testosterone was low ^[3].

That study is the closest the kisspeptin-10 literature comes to a real-world hypogonadal population. It was still a single infusion session in a research unit, not a course of treatment.

Is kisspeptin-10 stronger than GnRH or kisspeptin-54?

No. Kisspeptin-10 performs similarly to kisspeptin-54 for acute LH and FSH stimulation, and both isoforms are roughly three-fold weaker than GnRH given directly ^[4]. Kisspeptin-10 is a comparatively modest upstream stimulus one step higher in the signaling chain, not a stronger or more natural route to the endpoint that GnRH, hCG or clomiphene reach.

Does kisspeptin improve libido in men?

Kisspeptin-54 produced a pro-sexual effect in one trial in men with hypoactive sexual desire disorder. That double-blind, placebo-controlled crossover trial, the only randomized trial among the cited studies, found that kisspeptin infusion increased activity in brain regions tied to sexual and emotional processing (Cohen's d=0.81, P=0.003) and increased penile tumescence by up to 56% ^[5].

Both the peptide and the population differ from how the finding is repeated online. The trial used kisspeptin-54, not kisspeptin-10, and enrolled men with a diagnosed low-desire condition, not healthy men looking for a libido boost. Whether kisspeptin-10 has any of those effects is untested.

How was kisspeptin-10 dosed in the studies?

Every cited study gave kisspeptin-10 intravenously, because its circulating half-life is measured in minutes. The designs were an IV bolus ^[1], IV infusion at doses such as 0.3 nmol/kg ^[2], continuous IV infusion ^[3] and infusion at 1.0 nmol/kg/h ^[4]. Each was a single monitored research session with blood drawn at fixed intervals to track LH pulsatility in real time.

None of the studies used subcutaneous administration, and none used repeated dosing across days, weeks or months. A daily or every-other-day subcutaneous protocol is not a smaller, slower version of these trials. It is a different route and a different exposure pattern, and it raises a receptor question the cited literature does not answer: whether repeated, self-timed exposure stays on the stimulatory side of the dose-response and desensitization curve or drifts toward the suppression seen with continuous agonism of related receptors.

What is still unknown about kisspeptin-10?

The questions that matter most to people using it are the untested ones:

• Subcutaneous pattern. Whether any subcutaneous dosing frequency reproduces the pulsatile IV pattern that raised LH and testosterone in these trials, or instead produces gradual desensitization, is untested in the cited literature.
• Sexual effects. Whether kisspeptin-10, as opposed to kisspeptin-54, has any of the brain or tumescence effects seen in ^[5] has not been tested; that trial used a different peptide and a different patient population.
• Safety over months. Months of exposure outside a research setting sit entirely outside what these short clinical studies were designed to capture.

Kisspeptin-10 activates the reproductive axis in men under controlled, short-duration IV dosing, including men with metabolic disease and low testosterone ^[1]⁠^[3]. The current evidence does not show whether extended subcutaneous protocols produce any benefit, and the receptor biology gives a specific, testable reason to suspect the effect could run the other way. Related compounds such as gonadorelin as a testosterone therapy adjunct and hCG alongside testosterone therapy face similar gaps.